AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 16.5 |
Market Cap | 607.67M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -58.29 |
PE Ratio (ttm) | -0.31 |
Forward PE | n/a |
Analyst | Hold |
Ask | 19.4 |
Volume | 511,079 |
Avg. Volume (20D) | 791,924 |
Open | 18.74 |
Previous Close | 18.57 |
Day's Range | 17.85 - 19.33 |
52-Week Range | 12.33 - 24.92 |
Beta | undefined |
About GRAL
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated ...
Analyst Forecast
According to 2 analyst ratings, the average rating for GRAL stock is "Hold." The 12-month stock price forecast is $16, which is a decrease of -11.53% from the latest price.
1 month ago · marketwatch.com
World's biggest hedge fund flags the ‘holy grail' that may shield investors if U.S. stock rally crumblesKaren Karniol-Tambour, co-chief investment officer at Bridgewater Associates, says valuations are much higher for U.S. stocks than they were when the bull run began.